COVID-19 vaccine approved for trials, says Chinese military
The Chinese Ministry of National Defense (MND) announced on 18 March that a vaccine for the COVID-19 coronavirus, developed by the Academy of Military Medical Sciences of the People’s Liberation Army (PLA), has been approved for clinical trials.
The subunit vaccine has apparently been approved for safe testing on humans by an undisclosed (and therefore unverified) third party.
Preparations for mass production of the vaccine are also under way, the MND stated.
The team of PLA scientists worked under senior bioengineer Maj Gen Chen Wei. He has been conducting research in Wuhan, where the COVID-19 outbreak began.
A subunit vaccination includes a fragment of the pathogen that can initiate an immune response.
More from Defence Notes
-
US lawmakers warn that “more military spending is absolutely necessary” to ensure Pentagon’s readiness
The US Congress has raised concerns about how inflation rates and cuts in main acquisition programmes could affect the US military.
-
Can the US overcome Russian and Chinese nuclear capabilities?
Washington’s ageing inventory and the pace Moscow and Beijing have been modernising their capabilities put in check the US Nuclear deterrence.
-
US FY2024 funding package passes as China closes military capability gap
The Pentagon has been operating under temporary funding since October 2023, which has impacted its main acquisition and development programmes, increasing the capability gap between the US and China.
-
NATO outlines future challenges as Ukrainian funding from US stalls
In 2023, defence spending increased by an unprecedented 11% across European NATO countries and Canada. Since 2014, the group has spent an additional US$600 billion on defence.
-
US Pentagon to reduce investments in main acquisition programmes over FY2025
The DoD requested nearly US$850 billion to fund operations over the next fiscal year. Despite the amount being 1% higher than the FY2024 budget request, it has not covered the 3% inflation rate, which could impact the DoD’s main programmes in the medium and long term.